No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
IONS240719C47500
- 0.66
- -0.02-2.94%
15min DelayClose Jul 5 16:00 ET
0.66High0.66Low
0.66Open0.68Pre Close5 Volume1.06K Open Interest47.50Strike Price330.00Turnover33.50%IV4.49%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry0.66Extrinsic Value100Contract SizeAmericanOptions Type0.3458Delta0.1221Gamma68.28Leverage Ratio-0.0426Theta0.0058Rho23.61Eff Leverage0.0332Vega
Intraday
- 5D
- Daily
News
Is Ionis Pharmaceuticals (NASDAQ:IONS) Weighed On By Its Debt Load?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
6 analysts have shared their evaluations of Ionis Pharmaceuticals (NASDAQ:IONS) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table encapsulates th
Stifel Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Raises Target Price to $53
Stifel analyst Paul Matteis maintains $Ionis Pharmaceuticals(IONS.US)$ with a hold rating, and adjusts the target price from $50 to $53.According to TipRanks data, the analyst has a success rate of 46
Ionis Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 10.46% Stifel $50 → $53 Maintains Hold 06/14/2024 — Bernstein Upgrades Underperform → Market P
Express News | Ionis Pharmaceuticals Inc : Stifel Raises Target Price to $53 From $50
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
Comments
$Ionis Pharmaceuticals(IONS.US$
NEWS
“Ionis Pharmaceuticals announces positive Phase 3 results for olezarsen in treating familial chylomicronemia syndrome, showing significant reduction in triglycerides and acute pancreatitis events, potentially offering a breakthrough treatment option.
Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S.”
NEWS
“Ionis Pharmaceuticals announces positive Phase 3 results for olezarsen in treating familial chylomicronemia syndrome, showing significant reduction in triglycerides and acute pancreatitis events, potentially offering a breakthrough treatment option.
Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S.”
1
Ionis Pharmaceuticals' liabilities need constant monitoring despite its net cash indicating manageable debt. Future earnings are key for a healthy balance sheet. Its revenue growth suggests a path to profitability, but lack of profitability and cash burn make it risky.
2
Kyle Jenne's appointment, with his vast experience and previous tenure at Ionis, is expected to boost the company's commercial organization during a key growth period and product launches. His leadership is anticipated to help Ionis maximize the potential of its innovative medicines to reach patients and healthcare providers.
Recent insider selling at Ionis Pharmaceuticals may indicate insiders believe shares are overpriced. The absence of insider buying and history of sales could caution potential investors.
Investors might be overlooking potential risks as Ionis boasts a similar P/S ratio to the Biotech industry, despite weaker revenue outlook. Modest revenue growth could potentially put a downward pressure on the stock and put investments at risk.
Read more